Oragenics (NYSE:OGEN) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN) in a report released on Wednesday. The firm set a “sell” rating on the stock.

Oragenics Stock Performance

OGEN opened at $0.30 on Wednesday. The company has a market cap of $3.64 million, a PE ratio of -0.04 and a beta of 0.40. The stock has a 50-day moving average of $0.34 and a 200-day moving average of $0.62. Oragenics has a 52-week low of $0.25 and a 52-week high of $6.22.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.